Hikma Pharmaceuticals (LSE:HIK) Change In Receivables : £-19 Mil (TTM As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Hikma Pharmaceuticals Change In Receivables?

Hikma Pharmaceuticals's change in receivables for the quarter that ended in Dec. 2023 was £40 Mil. It means Hikma Pharmaceuticals's Accounts Receivable declined by £40 Mil from Jun. 2023 to Dec. 2023 .

Hikma Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2023 was £-19 Mil. It means Hikma Pharmaceuticals's Accounts Receivable increased by £19 Mil from Dec. 2022 to Dec. 2023 .

Hikma Pharmaceuticals's Accounts Receivable for the quarter that ended in Dec. 2023 was £623 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Hikma Pharmaceuticals's Days Sales Outstanding for the six months ended in Dec. 2023 was 99.44.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Hikma Pharmaceuticals's liquidation value for the six months ended in Dec. 2023 was £-952 Mil.

Hikma Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Hikma Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hikma Pharmaceuticals Change In Receivables Chart

Hikma Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

16.02

-34.97

-124.83

3.28

-18.96

Hikma Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Change In Receivables	Get a 7-Day Free Trial															-77.46	-5.68	9.03	-59.40	40.29

Hikma Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-19 Mil.

Hikma Pharmaceuticals (LSE:HIK) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Hikma Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	623.31	/	1143.92	*	91
=	99.44

2. In Ben Graham's calculation of liquidation value, Hikma Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Hikma Pharmaceuticals's liquidation value for the quarter that ended in Dec. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	180.91	-	1952.09	+	0.75 * 623.31	+	0.5 * 703.89
=	-952

Hikma Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Hikma Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Hikma Pharmaceuticals (LSE:HIK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hikma Pharmaceuticals PLC (LSE:HIK) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

HKMPY:USA HKMPF:USA HIKl:UK H5P:Germany

Address

1 New Burlington Place, London, GBR, W1S 2HR

Website

https://www.hikma.com

Hikma Pharmaceuticals PLC is engaged in the development, manufacture, and marketing of a broad range of generic, branded, and in-licensed pharmaceutical products. The firm operates in three segments: injectables, generics, and branded. The majority of the company's sales are based in the U.S. and to a lesser degree in the Middle East, North Africa, and Europe.

Hikma Pharmaceuticals (LSE:HIK) Headlines

No Headlines